228 related articles for article (PubMed ID: 34998466)
1. Genotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies.
Haslwanter D; Lasso G; Wec AZ; Furtado ND; Raphael LMS; Tse AL; Sun Y; Stransky S; Pedreño-Lopez N; Correia CA; Bornholdt ZA; Sakharkar M; Avelino-Silva VI; Moyer CL; Watkins DI; Kallas EG; Sidoli S; Walker LM; Bonaldo MC; Chandran K
Cell Host Microbe; 2022 Feb; 30(2):248-259.e6. PubMed ID: 34998466
[TBL] [Abstract][Full Text] [Related]
2. Isolation of a Potently Neutralizing and Protective Human Monoclonal Antibody Targeting Yellow Fever Virus.
Doyle MP; Genualdi JR; Bailey AL; Kose N; Gainza C; Rodriguez J; Reeder KM; Nelson CA; Jethva PN; Sutton RE; Bombardi RG; Gross ML; Julander JG; Fremont DH; Diamond MS; Crowe JE
mBio; 2022 Jun; 13(3):e0051222. PubMed ID: 35420472
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil.
Gonçalves AP; Almeida LT; Rezende IMd; Fradico JRB; Pereira LS; Ramalho DB; Pascoal Xavier MA; Calzavara Silva CE; Monath TP; LaBeaud AD; Drumond BP; Campi-Azevedo AC; Martins-Filho OA; Teixeira-Carvalho A; Alves PA;
Microbiol Spectr; 2024 May; 12(5):e0370323. PubMed ID: 38511952
[TBL] [Abstract][Full Text] [Related]
4. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.
Jiang X; Dalebout TJ; Lukashevich IS; Bredenbeek PJ; Franco D
J Gen Virol; 2015 Apr; 96(Pt 4):804-814. PubMed ID: 25516543
[TBL] [Abstract][Full Text] [Related]
5. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
[TBL] [Abstract][Full Text] [Related]
6. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K
mBio; 2020 Apr; 11(2):. PubMed ID: 32265332
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
Julander JG; Testori M; Cheminay C; Volkmann A
Front Immunol; 2018; 9():1756. PubMed ID: 30116244
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
Piras-Douce F; Broudic K; Chautard E; Raynal F; Courtois V; Gautheron S; Mantel N
Vaccine; 2023 Feb; 41(8):1457-1470. PubMed ID: 36702693
[TBL] [Abstract][Full Text] [Related]
9. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K
Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex.
Davis EH; Beck AS; Strother AE; Thompson JK; Widen SG; Higgs S; Wood TG; Barrett ADT
mBio; 2019 Oct; 10(5):. PubMed ID: 31641088
[TBL] [Abstract][Full Text] [Related]
11. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection
Douam F; Soto Albrecht YE; Hrebikova G; Sadimin E; Davidson C; Kotenko SV; Ploss A
mBio; 2017 Aug; 8(4):. PubMed ID: 28811340
[TBL] [Abstract][Full Text] [Related]
12. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.
Ma J; Yakass MB; Jansen S; Malengier-Devlies B; Van Looveren D; Sanchez-Felipe L; Vercruysse T; Weynand B; Javarappa MPA; Quaye O; Matthys P; Roskams T; Neyts J; Thibaut HJ; Dallmeier K
EBioMedicine; 2022 Sep; 83():104240. PubMed ID: 36041265
[TBL] [Abstract][Full Text] [Related]
13. Clinical evidence for the immunogenicity and immune persistence of vaccination with yellow fever virus strain 17D in Chinese peacekeepers deployed to Africa.
Jia Q; Jia C; Liu Y; Yang Y; Qi J; Tong L; Chen H; Zhang M; Che J; Li B; Li Z
Antiviral Res; 2019 Feb; 162():1-4. PubMed ID: 30529359
[TBL] [Abstract][Full Text] [Related]
14. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.
Sandberg JT; Ols S; Löfling M; Varnaitė R; Lindgren G; Nilsson O; Rombo L; Kalén M; Loré K; Blom K; Ljunggren HG
J Immunol; 2021 Aug; 207(4):1033-1043. PubMed ID: 34321231
[TBL] [Abstract][Full Text] [Related]
15. Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.
Tretyakova I; Nickols B; Hidajat R; Jokinen J; Lukashevich IS; Pushko P
Virology; 2014 Nov; 468-470():28-35. PubMed ID: 25129436
[TBL] [Abstract][Full Text] [Related]
16. The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells.
Watson AM; Lam LK; Klimstra WB; Ryman KD
PLoS Pathog; 2016 Jul; 12(7):e1005786. PubMed ID: 27463517
[TBL] [Abstract][Full Text] [Related]
17. Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants.
Daffis S; Kontermann RE; Korimbocus J; Zeller H; Klenk HD; Ter Meulen J
Virology; 2005 Jul; 337(2):262-72. PubMed ID: 15919103
[TBL] [Abstract][Full Text] [Related]
18. Comparative Infections of Zika, Dengue, and Yellow Fever Viruses in Human Cytotrophoblast-Derived Cells Suggest a Gating Role for the Cytotrophoblast in Zika Virus Placental Invasion.
Viettri M; Caraballo G; Sanchez ME; Espejel-Nuñez A; Betanzos A; Ortiz-Navarrete V; Estrada-Gutierrez G; Nava P; Ludert JE
Microbiol Spectr; 2023 Jun; 11(3):e0063023. PubMed ID: 37227282
[TBL] [Abstract][Full Text] [Related]
19. Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting.
Kareko BW; Booty BL; Nix CD; Lyski ZL; Slifka MK; Amanna IJ; Messer WB
J Infect Dis; 2020 Jun; 221(12):2018-2025. PubMed ID: 31545367
[TBL] [Abstract][Full Text] [Related]
20. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
